Aktienanalyse zu Attovia Therapeutics Inc (ATTO)ATTOAttovia Therapeutics Inc

Attovia Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases with high unmet need. Its lead pipeline candidates target commercially validated pathways and are designed through its ATTOBODY biologics platform to deliver improved treatments relative to the standards of care. Its ATTOBODY platform uses an evolution-driven, high-throughput process which allows for discovery and creation of a high diversity of potential product candidates. It is developing a pipeline of novel biotherapeutics for the treatment of immune-mediated diseases. Its first two product candidates for its immune-dermatology franchise, ATTO-1310 and ATTO-2306, have the potential to treat patients suffering from pruritic and lesional diseases. Its third program, ATTO-1091, broadens its reach to other inflammatory diseases, such as IBD, a therapeutic area with substantial unmet need. ATTO-1310 is an ATTOBODY-based therapeutic targeting interleukin-31. It operates in the Healthcare sector.

Attovia Therapeutics is not a good buy right now due to its current price of $13.73, which is significantly below the lowest analyst price target of $30, indicating potential upside. However, the stock has a very low RSI of 16.74, suggesting it is oversold, but the negative momentum and substantial losses in recent quarters raise concerns. The company reported a net loss of $20.69 million in Q2 2026, which is a risk to consider.